BNP Paribas Financial Markets Acquires 75,652 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

BNP Paribas Financial Markets boosted its holdings in REGENXBIO Inc. (NASDAQ:RGNX) by 370.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 96,093 shares of the biotechnology company’s stock after acquiring an additional 75,652 shares during the period. BNP Paribas Financial Markets owned 0.19% of REGENXBIO worth $743,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its holdings in shares of REGENXBIO by 67.0% in the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company’s stock valued at $31,975,000 after purchasing an additional 1,659,206 shares during the last quarter. Wells Fargo & Company MN raised its holdings in REGENXBIO by 34.0% in the 4th quarter. Wells Fargo & Company MN now owns 48,437 shares of the biotechnology company’s stock valued at $374,000 after acquiring an additional 12,285 shares during the period. Raymond James Financial Inc. acquired a new stake in REGENXBIO during the fourth quarter worth approximately $568,000. Price T Rowe Associates Inc. MD lifted its position in REGENXBIO by 9.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company’s stock worth $185,000 after acquiring an additional 1,982 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of REGENXBIO by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company’s stock worth $8,460,000 after acquiring an additional 5,574 shares during the period. Institutional investors own 88.08% of the company’s stock.

Insider Activity at REGENXBIO

In other news, Director Kenneth T. Mills sold 20,602 shares of the stock in a transaction on Monday, May 12th. The stock was sold at an average price of $7.91, for a total value of $162,961.82. Following the completion of the transaction, the director now directly owns 475,103 shares in the company, valued at approximately $3,758,064.73. This represents a 4.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.79% of the stock is currently owned by insiders.

REGENXBIO Stock Up 2.3%

RGNX stock opened at $9.86 on Friday. The company’s 50-day moving average price is $7.78 and its two-hundred day moving average price is $8.01. The firm has a market cap of $494.58 million, a P/E ratio of -1.96 and a beta of 1.11. REGENXBIO Inc. has a 12 month low of $5.04 and a 12 month high of $15.91.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.29). REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The business had revenue of $89.01 million during the quarter, compared to analyst estimates of $105.35 million. Equities analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. The Goldman Sachs Group lowered their target price on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, April 17th. Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research report on Tuesday, March 18th. Morgan Stanley upped their price target on shares of REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, March 14th. Chardan Capital reiterated a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research note on Thursday, March 20th. Finally, Wall Street Zen raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.63.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.